PLSE — Pulse Biosciences Balance Sheet
0.000.00%
- $1.18bn
- $1.08bn
- 35
- 16
- 26
- 13
Annual balance sheet for Pulse Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 20.5 | 28.6 | 61.1 | 44.4 | 118 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | 0.061 | 0 | — | — |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 22.3 | 36.6 | 62.1 | 45.3 | 119 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 11.9 | 11.2 | 10 | 8.78 | 8.32 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 41.3 | 54.2 | 77.9 | 59.2 | 132 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.58 | 8.52 | 5.98 | 6.71 | 10.1 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 18.4 | 18.6 | 80.1 | 14.8 | 17.6 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 22.9 | 35.7 | -2.25 | 44.4 | 115 |
| Total Liabilities & Shareholders' Equity | 41.3 | 54.2 | 77.9 | 59.2 | 132 |
| Total Common Shares Outstanding |